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Abstract
In Yaounde, Cameroon, HIV-1 group-specific V3 serology on 1469 HIV-positive samples collected between 1996 and 2001 revealed
that group O infections remained constant around 1% for 6 years. Only one group N sample was identified and 4.3% reacted with group
M and O peptides. Although the sensitivity of the group-specific polymerase chain reaction (PCR) in two genomic regions was not optimal,
we confirmed, in at least 6 of 49 (12.2%) dual O/M seropositive samples and in 1 of 9 group O samples, dual infection with group O and
M viruses (n  4) or with group O or M virus and an intergroup recombinant virus (n  3). Partial env (V3–V5) sequences on a subset
of 295 samples showed that at least eight subtypes and five circulating recombinant forms (CRFs) of HIV-1 group M co-circulate; more
than 60% were CRF02_AG and 11% had discordant subtype/CRF designations between env and gag. Similarly as for subtype B, the
proportion of syncytium-inducing strains increased when CD4 counts were low in CRF02_AG-infected patients. The V3-loop charge was
significantly lower for non-syncytium-inducing strains than for syncytium-inducing strains but cannot be used as an individual marker to
predict phenotype. The two predominant HIV-1 variants in Africa, CRF02_AG and subtype C, thus have different biological characteristics.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Phylogenetic analyses of numerous strains of HIV-1,
isolated from diverse geographic origins, have revealed that
they can be subdivided into groups (M, N, O), subtypes
(A–D, F–H, J, K), sub-subtypes (A1, A2; F1, F2) and
circulating recombinant forms (CRFs; CRF01–CRF14)
(Robertson et al., 2000). It was soon recognized that HIV-1
strains from Cameroon show a remarkable genetic diversity,
despite the initially low HIV prevalence. The three HIV-1
groups co-circulate and most of the known HIV-1 group M
variants have been described in Cameroon. HIV-1 groups O
and N were originally reported from this region and are
endemic to Cameroon and neighboring countries (De Leys
et al., 1990; Gurtler et al., 1994; Peeters et al., 1997; Simon
et al., 1998; Vanden Haesevelde et al., 1994). Several
unique and circulating recombinant forms have been de-
scribed, and recombination between HIV-1 group O and M
viruses has even been documented in Cameroon (Peeters et
al., 1999a; Takehisa et al., 1999). Although, several studies
have already reported the predominance of CRF02_AG in
Cameroon, the simultaneous presence of many HIV variants
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leads to the emergence of recombinant strains involving
divergent strains (Carr et al., 2001; Fonjungo et al., 2000;
2002; Heyndrickx et al., 2000; Montavon et al., 2000; Ny-
ambi et al., 2002; Tebit et al., 2002). Therefore, it remains
important to continue to genetically characterize prevalent
HIV-1 strains in regions where multiple variants co-circulate.
Continuous monitoring of the molecular epidemiology of
HIV-1 is also necessary because of all the implications
related to this diversity. There is well-established evidence
that differences related to efficiency of diagnostic assays
and antiretroviral drugs exist among the various HIV-1
variants (Apetrei et al., 1996, 1998; Descamps et al., 1997,
1998; Loussert-Ajaka et al., 1994; Parekh et al., 1999). The
degree to which vaccines based on one subtype will elicit
cross-protection against other subtypes is also still poorly
understood but the discovery of large numbers of recombi-
nant viruses clearly implies that co-infection with divergent
HIV-1 strains is not as rare as once thought (McCutchan,
2000; Peeters, 2000; van der Groen et al., 1998). Recent
studies have shown that there may also be differences in
pathogenesis among certain subtypes (Kaleebu et al., 2002;
Kanki et al., 1999).
Only a few data are available on the biological character-
istics of non-B HIV-1 strains, but from several independent
studies, it is clear that the CXCR4-positive phenotype, previ-
ously known as rapid/high or syncytium-inducing (SI), is rare
among subtype C-infected patients (Bjorndal et al., 1999;
Peeters et al., 1999b; Tscherning et al., 1998). For subtype B,
the presence of CXCR4-positive viruses is associated with a
more rapid progression to AIDS (Fenyo et al., 1988; Karlsson
et al., 1994; Koot et al., 1992, 1993; Tersmette et al., 1988,
1989), but it remains to be determined whether subtype C
infections are associated with different clinical outcomes. The
majority of HIV infections worldwide occur in Africa where
all HIV-1 variants co-circulate, but with subtype C predomi-
nating in South and East Africa and CRF02_AG in West and
West Central Africa (McCutchan, 2000; Peeters and Sharp,
2000). Since CRF02_AG is the second predominant HIV-1
variant in Africa, it is important to gain better knowledge of its
biological characteristics.
In this study, we report on the genetic and biological
characteristics of HIV-1 strains in a large cohort of patients
attending PRESICA, a health structure providing counsel-
ling, voluntary testing, and medical care for HIV-infected
patients in Yaounde, the capital city of Cameroon, between
1996 and 2001.
Results
Serologic prevalence of HIV-1 group M, N, and O and
HIV-2 infection among HIV-positive patients between
1996 and 2001
Over a 6-year period, from 1996 to 2001, 1469 samples,
identified as HIV positive by commercial screening and
confirmatory assays, were tested in an indirect ELISA based
on synthetic V3-loop peptides to discriminate between
HIV-1 group M, N, and O and HIV-2 infection. Overall,
1234 (84.0%; 95% confidence interval (CI), 82.1–85.9%)
samples were identified as group M, 15 (1.0%; CI, 0.6–
1.7%) samples were group O, 63 (4.3%; CI, 3.3–5.5%)
samples reacted with group M and group O V3-loop pep-
tides, and only 1 (0.1%; CI, 0.0–0.4%) sample reacted
strongly with group N. Only 3 (0.2%; CI, 0.0–0.6%) sam-
ples were identified as HIV-2, and 153 (10.4%; CI, 8.9–
12.1%) of the samples did not react with any of the V3-loop
peptides used. The proportion of group M infections fluc-
tuated from 1996 to 2001 between 78 and 90%, but differ-
ences were not significant over time (2 for trends, P 0.8).
Group O infections remained constant around 1% (0.8–
1.6%) within the limits of the CI, and about 10% (7.9–
11.7%) of the HIV infections could not be typed at each
period. The proportion of samples that reacted simulta-
neously with group O and M peptides fluctuated over time,
but no significant trend was seen (2 for trends, P  0.9).
HIV-1 group M variants
A subset of the 1469 patients (n  295) agreed to be
enrolled in a previously described cohort study that moni-
tors whether different subtypes are associated with different
disease progression or pathogenesis (Laurent et al., 2002).
Samples from these patients were genetically characterized
and can be considered representative of the complete HIV-
infected population, without any biases in the subtype dis-
tributions. The genetic subtype was identified in the env
V3–V5 region for these 295 samples, and for 118 of them,
chosen at random, the subtype was also characterized in the
gag p24 region. Among the 295 samples, 278 were reactive
with the group M V3 peptide, and 17 were untypable in the
peptide ELISA. Fig. 1 summarizes the genetic subtypes in
the env V3–V5 region for the 295 samples. Overall, at least
eight subtypes and five CRFs co-circulate in HIV-1 group
M-infected patients in Yaounde. The majority of the strains
(80.8%) belonged to subtype A, but a more detailed phylo-
genetic tree analysis showed that many strains formed a
separate subcluster with the CRF02_AG prototype strains,
representing 62.7% of the total amount of HIV-1 infections.
Among the remaining env subtype A samples, some clus-
tered with CRF11_cpx, CRF13_cpx, or the A reference
strains, and a separate subcluster that we identified for
clarity as A* was also observed (Fig. 2a), representing 4.8,
0.3, 8.2, and 4.8% of the total infections, respectively (Fig.
1). Almost all other known genetic subtypes co-circulated:
0.3% B, 0.3% C, 4.4% D, 0.3% F1, 6.4% F2, 3.1% G, 2.1%
H, 0.3% K; two other CRFs were also present, 0.3%
CRF01_AE and 1.7% CRF06_cpx (Fig. 1). Only one sub-
type F strain belonged to the F1 sub-subtype; all the others
were F2. The majority of the env subtype D strains formed
a separate and well-supported subcluster within subtype D
(Fig. 2a). Previously described unusual env sequences from
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Cameroon (Cam001C and BCB88), initially proposed to
form a new env clade designated “k” (Loussert-Ajaka et al.,
1998; Roques et al., 1999), also clustered with our subtype
D viruses. Similar subtype D variants were recently also
documented by our group in Chad, and full-length genomes
were sequenced for two such strains (99TCD-MN011 and
99TCD-MN012) showing that these strains represent a pure
subtype D variant restricted to West Central Africa (sub-
mitted for publication).
The genetic subtype was also identified in 17 samples
that were untypable by V3-group specific serology (17 of
153 untypables, 11.1%); all 17 were group M and the
subtype distribution was as follows: 9 CRF02_AG, 1 A, 2
D, 1 H, 2 F2, and 2 CRF11. No significant differences were
observed in the V3-loop sequences of these samples com-
pared with the V3-consensus sequences for each subtype.
For 118 samples subtyped in env, we also genetically
characterized the gag p24 region to estimate the proportion
of recombinant strains. For 28 (24%) and 78 (66%) strains,
subtype and CRF designations, respectively, were concor-
dant between the two genes studied (Table 1). For 12 (10%)
samples, the subtype/CRF designations were discordant be-
tween the two genes studied (Table 1). For 2 of the 12
discordant samples, two different subtypes were noted, but
for the remaining 10 strains, the discordance was noted
between a CRF and a subtype. Similarly as observed
among the env sequences, gag subtype D sequences
formed a separate subcluster within subtype D and the env
subtype A sequences, designated as A* in env, clustered in
the gag region with the CRF01_AE prototype strains (Fig.
2b). This cluster also contained the CM53122 strain from
Cameroon, for which full-length genome analysis revealed
Fig. 2. Identification of new subclusters in subtypes A and D: phylogenetic trees based on 499-bp unambiguously aligned nucleotides from the V3–V5 env
region (a) and 669-bp unambiguously aligned nucleotides from the p24 gag region (b). The following reference strains representing the different subtypes
and CRFs were used: subtype A (A_KE.93.Q2317, A_UG.92.UG307, A_SE.94.SE7253); subtype B (B_US.86.JRFL, B_US.90.WEAU160,
B_FR.83.HXB2R); subtype C (C_ET.86.ETH2220, C_IN.95.21068, C_BW.96.BW0502, C_BR.92.BR025); subtype D (D_CD.83.NDK, D_CD.83.ELI,
D_UG.94.UG114, D_ 99TCD.MN011, D_99TCD.MN012); sub-subtype F1 (F1_FR.96.MP411, F1_BE.93.BEVI850, F1_FI.93.FIN9363); sub-subtype F2
(F2_CM.95.MP255, F2_CM.95.MP257); subtype G (G_NG.92NG083, G_SE.93.SE6165, G_BE.96.DRCBL); subtype H (H_BE.93.VI991, H_BE.93.VI997,
H_CF.90.CF056); subtype J (J_SE.93.SE7887, J_SE.94.SE7022); subtype K (K_CM.96.MP535, K_CD.97.EQTB11); CRF01_AE (AE_TH.93.TH253,
AE_TH.90.CM240, AE_CF.90.CF402, AE_CF.90.CF4071); CRF02_AG (AG_IBNG, AG_FR.91.DJ263, AG_CM.97.MP807, AG_SE.98.MP1211,
AG_SE.98.MP1213); CRF06_cpx (96.BFP90, 95.ML84, 95.ML127), and CRF11_cpx (97.CM-MP818, 99.FR-MP1298, 99.FR-MP1307). The phylogenetic
analysis was done as described under Materials and Methods. Reference strains are in black; our strains forming an A* subcluster and a DCM subcluster (D
in Cameroon) are in gray. The CM53122 strain (marked by Œ) from Cameroon has been considered as a reference of CRF01_AE/A recombinant (Carr et
al., 2001) and clustered with our group A*.
Fig. 1. Distribution of HIV-1 group M variants (in percentage) in Yaounde, the capital city of Cameroon. The data are based on partial env (V3–V5)
sequences.
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that it was a CRF01_AE/A recombinant strain (Carr et al.,
2001).
Genetic characterization of dual group O and M
seropositive samples
Among the 1469 sera tested in the V3-loop ELISA, 63
(4.3%) reacted simultaneously with HIV-1 group M and
group O V3 peptides. In 49 samples, for which sufficient
material was available, additional PCR analyses with spe-
cific group M and group O primers in pol (partial integrase)
and env (C2-V3 and/or partial gp41) were done to study
whether these individuals were infected with both group M
and group O viruses. Each PCR product was sequenced to
verify the specificity of the group-specific primers. As con-
trols, we performed similar analyses on 9 samples that
reacted only with group O V3 peptides and on 10 samples
that reacted only with group M V3 peptides. The dual-
reactive samples were classified into three categories, ac-
cording to the optical density (OD) observed with each
peptide. Table 2 summarizes the PCR results for the differ-
ent categories of dual-reactive samples and for the group O
and group M control samples. Among the 34 samples with
higher reactivity with the M-V3 peptide, only 1 dual infec-
tion was documented by PCR. In this sample (MP977), O
and M viruses were amplified in pol and env. Both O and M
viruses were confirmed by sequence and phylogenetic tree
analysis of the C2-V3 region (Fig. 3). For the 14 samples
with equal reactivities to group M and O peptides, 8 were
infected with a group M virus only, 1 with a group O virus
only; in 2 patients (MP647, MP1289), O and M sequences
were amplified in pol and env (Fig. 3); and in 2 others
(283BA, MP978), only M sequences were amplified in pol
and O and M sequences in env (Fig. 3), suggesting co-
existence of a group M virus and a possible intergroup
recombinant virus. One of these samples was from a patient
for whom we previously documented dual infection with
group M and an intergroup M–O strain, based on full-length
genome sequencing (Peeters et al., 1999a). The intergroup
recombinant strain was M in the 5 end of the genome and
O in the 3 end, with a breakpoint in vif. In the only sample
with a higher reactivity with the O-V3 peptide (2734BA),
both group O and M sequences were amplified in pol and
env (Fig. 3). For two dual-reactive samples, no conclusion
could be drawn because no virus could be amplified in pol
or env with the group O- and M-specific primers.
Surprisingly, for one of the nine samples reacting with
only the group O V3 peptide (273BA), the presence of at
least two viruses was documented. In this sample, M and O
were amplified in env (Fig. 3) and only O in pol. This could
suggest the presence of dual infection with a group O virus
and an intergroup recombinant virus being O in the 5 end
of the genome and M in the 3 end. For two group O
samples, no conclusion could be drawn because no virus
could be amplified in pol or env with the group O- and
M-specific primers.
For the 10 samples that reacted only with group M
peptides, only group M sequences were amplified. Fig. 3
shows the phylogenetic tree in the env C2-V3 region con-
firming the simultaneous presence of group O and M se-
quences. Overall, this means that at least in 6 of 49 (12.2%)
dual-seropositive samples, dual infection was documented,
as it was in 1 of 9 (11.1%) group O monoreactive samples.
Syncytium-inducing capacity of non-B HIV-1 group M
strains in Cameroon
Classification of viral isolates as SI or non-SI (NSI) is
considered to be important for the prognosis of disease
progression, and the appearance of SI variants is related to
enhanced CD4 cell depletion and disease progression to
AIDS in subtype B infections. Few data exist on the bio-
logical characteristics of CRF02_AG strains which are pre-
dominant in the HIV epidemic in West and West Central
Africa. For the patients included in the cohort, viral cultures
were attempted. For 168 randomly chosen HIV-1 strains the
SI capacity was also studied on MT-2 cells as previously
described. For the different subtypes, data were correlated
to disease stage of the patients as reflected by their CD4
counts. Table 3 summarizes the number and/or percentage
of SI strains, according to the CD4 counts and for the
different env subtypes. Similarly as observed in subtype
B-infected patients, more SI strains are observed in patients
at a more advanced disease stage: 54.7% SI strains in
patients with fewer than 200 CD4 cells/mm3, 27.5% SI
strains at CD4 counts between 200 and 500 cells/mm3, and
12.5% SI strains at CD4 counts above 500 cells/mm3. Only
for the CRF02_AG strains, which represent 61.3% of the
Table 1
Subtypes in gag (p24) and env (V3–V5) for 118 HIV-1 group M
samples
gag env n
Concordant genotypes between
gag and env
Concordant subtypes (24%) A A 9
B B 1
D D 3
F2 F2 10
K K 1
G G 4
Concordant CRFs (66%) CRF02 (A) CRF02 (A) 69
CRF06 (A) CRF06 (G) 1
CRF11 (A) CRF11 (A) 7
CRF13 (G) CRF13 (A) 1
Discordant genotypes between
gag and env
Discordant subtype/CRF
designations (10%)
A H 1
D A 1
CRF02 A* 1
A CRF02 1
CRF02 H 1
CRF02 F2 1
CRF01 A* 6a
a This group of viruses could represent a new CRF.
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strains tested, could significant conclusions related to the
subtype be drawn; for the other variants the numbers tested
were too low: 55.8% of the CRF02_AG strains were SI in
patients with fewer than 200 CD4 cells/mm3, 20.0% were SI
when CD4 counts were between 200 and 500 cells/mm3,
and 20.0% were SI when CD4s were above 500 cells/mm3.
Similarly as previously reported for subtype B strains,
we studied the prediction of the phenotype based on the
sequence of the V3 loop; i.e., we examined whether posi-
tively charged amino acids at positions 11 and/or 25 in the
V3 loop were present, and calculated the global charge of
the V3 loop (Resch et al., 2001). All V3-based phenotype
predictions are summarized in Table 4. Among the 108 NSI
strains in vitro, 103 (95.4%) were predicted as NSI and 5
(4.6%) were predicted as SI based on the presence of a
positive charged amino acid at position 11 or 25, with R (n
 3) and K (n 2) in position 25 only. For the 60 SI strains
in vitro, only 20 (33.3%) had a positive amino acid at one of
these two positions, with R (n  10) and H (n  2) at
position 11 and with R (n 4) and K (n 5) at position 25.
Only a significant number of CRF02_AG strains were
analyzed and a similar trend was seen: 64 (95.5%) of the 67
NSI strains were predicted to be NSI and only 12 (33.3%)
of the 36 SI strains were predicted to be SI. Although the
numbers of subtype D samples were very low, this was the
only subtype in our study where all SI strains were predicted
SI based on the amino acids present at positions 11 and/or
25.
The mean global charge of the V3 loop was significantly
lower for NSI strains, 4.25 ( 0.88), versus SI strains, 5.40
 1.30 (P  104). This was also the case for CRF02_AG
separately, 4.16  0.91 for NSI strains versus 5.42  1.36
for SI strains (P  104). For subtype B, NSI strains have
a total net charge between 2 and 4 and SI strains have
a charge superior to 4. However, the global charge cannot
be used as an individual marker to predict whether strains
are SI or NSI, since only 66 of 108 (61%) NSI strains have
a charge 4 predicting NSI strains for subtype B, and 45 of
60 (75%) have a charge 5 which predicts SI strains for
subtype B (Table 4). Predicting the phenotype based on the
global V3 charge was more sensitive than the method based
on positively charged amino acids at position 11 and/or 25
(75% vs 33.3%) but less specific (61.1% vs 95.4%) (Table
4). These two methods were established on subtype B, with
a better performance (sensitivity: 83% vs 84%; specificity:
93% vs 97%) (Resch et al., 2001) and cannot be used on
non-B strains.
Discussion
In addition to previous studies on molecular epidemiol-
ogy in Cameroon, this current study highlights the preva-
lences of groups M, N, and O over time, documents dual
group M and O infection and intergroup recombinants, and
describes biological characteristics of the predominant
CRF02_AG variant.
HIV-1 groups O and N were both first identified in
Cameroon, raising concern over the emergence of new HIV
variants, with possible public health implications (Loussert-
Ajaka et al., 1994). In this study, we showed that group O
prevalences remained low and constant, representing
around 1% of the HIV-1 infections between 1996 and 2001.
Previously, Ayouba et al. (2001) showed, for samples col-
lected between 1986 and 1998, that group O infections
decreased in Cameroon from 20.6% in 1988 to 1.4% in
1998. These data and our subsequent stable prevalences
suggest that group O infection seems to be stabilized. We
Table 2
PCR results with specific group O and M primers in pol and env (C2V3) for the different categories of dual O/M seropositive samples and for the group
O and group M control samples
Dual reactive samples (n  49) Group O
samplesd
(n  9)
Group M
samplese
(n  10)
Total
OD O  Ma
(n  1)
OD M  Ob
(n  14)
OD M  Oc
(n  34)
pol M, env M — 8 32 — 10 50
pol O, env O — 1 — 6 — 7
pol MO, env MOf 1 2 1 — — 4
pol M, env MOg — 2h — — — 2
pol O, env MOg — — — 1 — 1
PCR neg with M and O
in one of the two genes
— 1 1 2 — 4
a OD with M-V3 peptide  0.605 and OD with O-V3 peptide  2.869.
b Mean OD with M-V3 peptide  0.997 (0.386–1.687) and mean OD with O-V3 peptide  0.950 (0.313–1.624).
c Mean OD with M-V3 peptide  1.181 (0.703–2.283) and mean OD with O-V3 peptide  0.538 (0.371–1.077).
d OD with M-V3 peptide  0.250 and mean OD with O-V3 peptide  0.947 (0.345–1.546)
e Mean OD with M-V3 peptide  0.699 (0.374–1.205) and OD with O-V3 peptide  0.250.
f These combinations of PCR results suggest infection with a group O virus and a group M virus.
g These combinations of PCR results suggest infection with a group M or O virus and an intergroup recombinant virus.
h Based on full-length genome sequence for one sample, an intergroup O/M recombinant virus has been previously reported on a follow-up sample from
this patient (Peeters et al., 1999a).
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also confirm in our study that group N is still a rare infec-
tion—only 1 (0.1%) group N infection in a total of 1469
HIV-1 samples (Ayouba et al., 2000).
Although the group-specific V3-loop peptide ELISA has
limitations, it allows rapid screening of large numbers of
samples to differentiate between HIV-1 groups. In addition,
the technique is easy and can be easily implemented in
developing countries where different HIV-1 groups co-cir-
culate. As already previously described, the technique lacks
sensitivity and cross-reactions between M and O are ob-
served (Simon et al., 2001). Around 10% of our samples
could not be typed; this is in concordance with results
reported by Simon and colleagues on serum panels from
Cameroon and Gabon (Simon et al., 2001). Lack of reaction
with the V3 peptides may be due to low titers of V3
antibodies, suboptimal consensus sequences for the group
M, O, or N peptides, or infection with divergent HIV
strains. To test this latter possibility, we sequenced 17
untypable samples which represented 11.1% of the total
untypable samples; all were group M strains without any
particular V3-loop sequence. We also observed that a rela-
tively significant number of the HIV-positive samples, 63
(4.3%), had simultaneously antibodies against group O and
group M peptides. On a reference panel of 72 group M and
28 group O sera, Simon et al. (2001) showed that 2.8% of
group M samples cross-reacted with the group O peptide
and 29% of group O samples cross-reacted with group M
peptide, but all groups reacted with the correct peptide and
cross-reactions represent optical densities that are 50%
lower. Our prevalences of dual O/M seropositivity corre-
spond to the 5.7% documented by Simon and colleagues on
a serum panel from Cameroon (Simon et al., 2001). We
checked by PCR and sequencing the presence or not of
group M and O viruses on a subset of 49 dual-seropositive
Fig. 3. Phylogenetic tree based on 364-bp aligned nucleotides from the C2V3 env region for the dual seropositive samples in which group O and M sequences
were amplified in env. The following reference strains representing group O strains and different group M subtypes and CRFs are as follows: O_CM.ANT70,
O_GQ.276HA, O_GA.92.VI686, O_SN.99.SEMP1299, O_SN.99.SEMP1300, O_GQ.193HA, O_CM.93.CA9EN, O_CM.91.MVP5180, O_CM.4974;
A_KE.93.Q2317, A_UG.92.UG307, A_SE.94.SE7253, A_SE.94.SE7535, B_GA.88.OYI, B_FR.83.HXB2R, C_BW.96.BW0402, C_BR.92.BR025,
D_CD.83.NDK, D_CD.83.ELI, F1_FR.96.MP411, F1_F1.93.FIN9363, F2_CM.95MP255, F2_CM.95MP257, G_SE.93.SE6165, G_BE.96.DRCBL,
AE_TH.90.CM240, AE_CF.90.CF402, AG_IBNG, AG_FR.91.DJ263. An outgroup CPZ_CD.CPZANT was used.
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samples, and documented the presence of at least two vi-
ruses in six samples. Moreover, in one sample reactive with
only the group O peptide, we also documented dual infec-
tion. Different combinations of dual infections were docu-
mented; dual infection with groups O and M, dual infection
with group O or M virus and an intergroup recombinant
virus, with group M in the 5 end and group O in the 3 end,
or vice versa. This means that at least in 7 (0.5%) of the
1469 HIV-1 infected patients, dual infection occurred, with
the possible presence of an intergroup O/M recombinant in
three patients. The minimal estimate of a 0.5% prevalence
of dual infections is thus very close to the 1.0% of group O
infections. Therefore, it will be important to monitor also
for dual group M and O infection in Cameroon because
recombination between strains belonging to distant lineages
may contribute substantially to the emergence of new
HIV-1 variants.
Our study also shows that group-specific PCR in two
regions of the genome is an easy and specific tool with
which to detect dual infections. The primers that we used in
our study were validated with high sensitivities and speci-
ficities on viral isolates, whereas in our study the sensitivity
could be lower because we started on primary material
(plasma and/or PBMCs). The suboptimal storage conditions
(20°C for long periods) and lower viral loads in primary
material can significantly decrease the sensitivity of the
PCRs. However, the primers used were specific, since all
fragments amplified with group-specific primers were con-
firmed by sequencing (data not shown, only for the dual-
reactive samples in Fig. 3). This means that the numbers of
dual infections (6/49) are minimal estimates and could prob-
ably be even higher. These intergroup recombinations could
have important implications for diagnosis of HIV-1 infec-
tions by serological and molecular tests, and for treatment
since differences among susceptibilities to nonnucleoside
reverse transcriptase inhibitors (NNRTIs) exist between
group O and group M (Descamps et al., 1997; Loussert-
Ajaka et al., 1994). Actually, the low prevalence of group O
infections does not yet compromise the use of nevirapine as
prophylaxis for mother-to-child transmission of HIV, but
our observations and other reports on dual infections sug-
gest that intergroup O/M recombinants should also be mon-
itored (Peeters et al., 1999a; Takehisa et al., 1997, 1999).
Continuous monitoring of the different HIV-1 groups in
Cameroon is also necessary to document the stabilization or
decline of group O infection and the extent of dual infec-
tions and possible intergroup recombinants, and to find out
whether group N is an emerging or declining HIV infection.
To accurately identify group M and group O infection, the
sensitivity of the V3-peptide assay has to be improved. The
relatively low rate of confirmed dual infections, 12.2%,
along dual-M/O-seropositive samples can be related to
false-positive reactions, with one peptide, but also to the
fact that one of the two viruses became predominant during
Table 3
Number and/or percentage of SI and NSI strains, according to the CD4 counts and for the different env (V3–V5) subtypes
env subtype 200 CD4 cells/mm3 200–500 CD4 cells/mm3 500 CD4 cells/mm3 n tested
SI NSI SI NSI SI NSI
A 0 5 6 9 0 3 23
C 0 1 0 0 0 0 1
D 2 0 1 4 0 1 8
F 4 0 4 2 0 2 12
G 1 1 0 2 0 2 6
H 2 0 0 1 0 0 3
K 0 1 0 0 0 0 1
CRF02 24 (55.8%) 19 9 (20.0%) 36 3 (20.0%) 12 103
CRF06 0 2 1 1 0 0 4
CRF11 2 0 1 3 0 1 7
Total 35 (54.7%) 29 22 (27.5%) 58 3 (12.5%) 21 168
Table 4
Performance of V3-based phenotype prediction methods in non-B subtypesa
Rule (prediction) NSI
(n  108)
SI
(n  60)
Sensitivity Specificity
Positively charged amino acid
at 11 or 25
nsi 103 40 33.3% 95.4%
si 5 20
Global charge nsi 66 15 75% 61.1%
si 42 45
a Uppercase and lowercase letters denote experimentally determined phenotypes (NSI or SI) and predicted phenotypes (nsi or si), respectively. Sensitivity,
fraction of correctly identified SI sequences; specificity, fraction of correctly identified NSI sequence (Resch et al., 2001).
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HIV infection with viral loads under the detection limit,
resulting in a negative PCR for the other infecting strain, but
with persistence of specific antibodies. In addition, dual
M/O infection was confirmed in one sample that reacted
only with the group O peptide. This can probably be ex-
plained by the limit of the V3-peptide ELISA in which 10%
of the samples remain untypable and thus not all group M
infections are detected.
Based on partial env sequences, we demonstrated, in a
random sample (n  295), a high genetic diversity among
HIV-1 group M strains, with at least eight subtypes and five
CRFs that co-circulate. CRF02_AG is the predominant vari-
ant, representing more than 60% of the total HIV-1 infec-
tions. Within env subtype A sequences, we identified a
separate subcluster, which we identified as A* for clarity in
the text and figures, and the same strains clustered in gag
with the CRF01_AE prototype strains. These strains clus-
tered with the previously described CM53122 strain from
Cameroon which is a mosaic virus between CRF01_AE and
nonrecombinant subtype A (Carr et al., 2001). Heyndrickx
et al. (2000) also identified three viruses as CRF01_AE in
gag and A in env. It is thus possible that all these strains
have a similar mosaic genome structure and represent a new
CRF. Significant conclusions can be drawn only after se-
quencing two additional full-length genomes from epidemi-
ologically unlinked individuals. In our study, 10% of the
samples had discordant subtype/CRF designations between
gag and env, and in the majority of the samples, CRF02_AG
was involved in the possible recombination event, thus
leading to more complex viruses.
In the present study, we evaluated the presence of SI and
NSI variants in patients infected mainly with the
CRF02_AG variant which predominates in West and West
Central Africa. After stratification for CD4 counts, we ob-
served similarly as for subtype B-infected patients (Fenyo et
al., 1988; Karlsson et al., 1994; Koot et al., 1992, 1993;
Tersmette et al., 1988, 1989) that the proportion of SI strains
increases when disease is more advanced and CD4 counts
are lower. We can therefore conclude that the biological
characteristics of the CRF02_AG strains are similar as those
seen in subtype B-infected patients in Europe and the
United States. It is, however, important to note that the two
predominant HIV-1 variants in Africa, CRF02_AG and
subtype C, have different biological characteristics. Multi-
ple reports have shown that CXCR4 usage as well as MT-2
cell tropism was rare among subtype C samples (Bjorndal et
al., 1999; Peeters et al., 1999b; Tscherning et al., 1998).
For subtype B, positively charged amino acids are found
at positions 11 and/or 25 in the V3 loop of SI isolates,
whereas in NSI isolates both residues were either uncharged
or negatively charged (De Jong et al., 1992; Fouchier et al.,
1992). However, in our study, 95.4% of the NSI strains in
vitro were predicted NSI, but only 33.3% of the SI strains
were predicted SI, suggesting that the in vitro detection of
SI variants cannot be replaced by a genetic method for
CRF02. Other reports also observed a lack of correlation
between the V3-loop amino acid sequence and the in vitro
SI capacity of some HIV-1 isolates, and this lack of corre-
lation is observed among different genetic subtypes includ-
ing subtype B (Holm-Hansen et al., 1995; Peeters et al.,
1999b; Sabri et al., 1996). Similarly, despite the fact that the
global charge of the V3 loop was significantly lower for NSI
strains, this cannot be used as an individual marker to
predict whether strains are SI or NSI.
Our study also shows that co-infection and recombina-
tion between divergent HIV-1 strains is thus not as rare as
initially thought. To develop an efficient vaccine, it remains
to be determined when superinfection can occur during the
course of HIV infection, and to what extent humoral and
cellular antibody responses are efficient against divergent
strains. Differences between transmissibility and pathoge-
nicity have been well documented for HIV-1 and HIV-2,
with HIV-2 being less transmissible and less pathogenic
than HIV-1 (De Cock et al., 1993; Kanki et al., 1994;
Marlink et al., 1994). Whether similar differences exist
among the HIV-1 groups and/or subtypes has to be studied
further. Recently, a study in Uganda documented on more
than 1000 patients that compared with subtype A, subtype D
is associated with a faster progression to disease (Kaleebu et
al., 2002). We recently showed that patients infected with
the CRF02_AG variant have a progression to disease sim-
ilar to that of patients infected with non-CRF02_AG strains
(Laurent et al., 2002). Associations between modes of trans-
mission and subtype are probably due more to historical
chance coupled with behavioral factors, but biological fac-
tors related to the host and the virus could also play a role
(Hu et al., 1999; Kunanusont et al., 1995; van Harmelen et
al., 1997). NSI variants seem to be more readily transmitted
than SI variants (Cornelissen et al., 1995; Zhu et al., 1993).
Therefore, it is important to follow-up whether the spread of
certain variants, for example CRF02_AG and subtype C, in
Africa could be associated with their biological character-
istics.
Materials and methods
Patients and serology
All HIV-1-positive samples from patients attending
PRESICA, a health structure providing counselling, volun-
tary testing, and medical care for HIV-infected patients
based at the military hospital in Yaounde, were systemati-
cally tested to differentiate between HIV-1 group O, M, and
N and HIV-2 infection, over a 6-year period (1996–2001).
The military hospital in Yaounde, the capital city, is one of
three major referral centers for patients with suspected HIV-
related disease. Most patients are referred directly to
PRESICA from other hospitals or primary health care fa-
cilities for suspected HIV-related diseases or for HIV
screening. Since January 1997, a cohort study has been
initiated to study the impact of the different genetic sub-
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types/CRFs on disease progression. Patients identified as
HIV infected who were more than 14 years old, and with a
Karnofsky index greater than 70, were asked to participate
in this cohort study. The patients enrolled in the cohort were
asked to attend medical examinations quarterly or more
often if necessary. Immunological status was recorded at
baseline and then every 6 months; the genetic subtype was
identified and when possible viral cultures were attempted.
All patients received pre- and posttest counselling, and HIV
testing was done after written informed consent was re-
ceived from the patient. All clinical and laboratory tests
were free of charge at the initial visit, as were medical visits
and laboratory tests at follow-up for those participating in
the cohort. Free medical care, including prophylaxis and
treatment of opportunistic infections, was offered to each
patient with a positive HIV serology.
Screening for HIV-1 antibodies was performed by
ELISA (Murex HIV-1.2.0, Abbott, Rungis, France) fol-
lowed by confirmation on a Line immunoassay, INNOLIA
HIV-1/HIV-2 (Innogenetics, Belgium). CD4 cell counts
were determined by flow cytometry (FACSCount, Becton
Dickinson, Mountain View, CA, USA) in freshly collected
whole blood at baseline and then every 6 months. Since
2001, antiretroviral drugs (ARVs) have been offered to all
patients with medical criteria, based on their clinical evo-
lution and CD4 counts as defined in a consensus report on
the place of ARVs in Africa (IAS, 1999).
To differentiate between HIV-1 group O, M, and N and
HIV-2 infection, sera were tested with an in-house indirect
ELISA based on synthetic V3-loop peptides of HIV-1-M,
-N, and -O, and HIV-2, as previously described (Simon et
al., 2001). Briefly, wells of microtiter plates were coated
with 0.25 g of each single peptide per well in 0.05 M
bicarbonate buffer, pH 9.6, by incubation at 37°C for 20 h.
After washing with phosphate-buffered saline (PBS) con-
taining 0.5% Tween 20, unoccupied sites were blocked with
PBS containing 5% fetal calf serum, for 2 h at 37°C. Sera
were diluted 1/100 in an hypertonic PBS solution (0.01 M
sodium phosphate buffer, pH 7.4, containing 0.75 M NaCl,
10% fetal calf serum, and 0.5% Tween 20). After incubation
for 30 min at room temperature, plates were washed and
incubated with peroxidase-conjugated goat anti-human IgG
for 30 min at room temperature. After washing, the reaction
was revealed with hydrogen peroxide–o-phenylendiamine
for 15 min at room temperature in the dark. Color develop-
ment was stopped by adding 2 N H2SO4, and OD was read
at 492 nm.
Genetic subtyping in the gag and env regions
Blood was collected into EDTA tubes, and plasma and
cells were separated and stored at 20°C. DNA was ex-
tracted from the primary or cultured peripheral blood mono-
nuclear cells (PBMCs) using the Qiagen DNA isolation kit
(Qiagen SA, Courtaboeuf, France), according to the manu-
facturer’s instructions.
Seven hundred-base pair fragments, corresponding to the
p24 region from the gag gene and the V3–V5 env region,
were amplified as previously described by a nested PCR
(Toure-Kane et al., 2000). The amplified fragments were
purified using the QIAquick gel extraction kit (Qiagen) and
were directly sequenced with the Abiprism BigDye Termi-
nator Cycle Sequencing Ready Reaction Kit with AmpliTaq
DNA polymerase (FS; Perkin–Elmer, Roissy, France) on an
automated sequencer (373A stretch; Applied Biosystems).
Identification of HIV-1 group O and M sequences in dual
group O and M seropositive samples
Plasma or primary PBMCs from dual-seropositive sam-
ples were tested by RT-PCR or PCR respectively, with
group M- and group O-specific primers in env (C2V3 and
gp41) and pol (partial integrase), to confirm the simulta-
neous presence of both viruses. The group M C2V3 frag-
ment was amplified with a nested PCR using previously
described group-M specific primers ED5/ED12 as the out-
ers, and ED31/ED33 as the inners under previously de-
scribed PCR conditions (Delwart et al., 1993). The HIV-1
group O C2V3 region was amplified as previously described
in a nested PCR with the following primers as outers,
V70.1: 5-TTGTACACATGGCATTAGGCCAACAG-
TAAGT-3
V70.5: 5-GTTCTCCATATATCTTTCATATCTCCC-
CCTA-3
and as inners,
V70.2: 5-TGAATTCCTAATATTGAATGGGACAC-
TCTCT-3
V70.4: 5-TGGATCCTACAATAAAAGAATTCTCC-
ATGACA-3
(Peeters et al., 1997). Although the sensitivity of the
C2V3 group O primers was high (first and second round
specific to group O), an additional PCR was done in the
gp41 region on the samples remaining negative with
group O-specific primers in the C2V3 region. A nested
PCR was done with universal group M and O primers as
outers,
gp41.1: 5-GGGTTCTTGGGAGCAGCAGGAAGCA-
CTATGGGCG-3
gp41.4: 5-TCTGAAACGACAGAGGTGAGTATCC-
CTGCCTAA-3
and with group O-specific primers as inners,
gp41.6: 5-TGGATCCCACAGTGTACTGAAGGGT-
ATAGTGCA-3
gp41.7: 5-CATTTAGTTATGTCAAGCCAATTCCA-
AA-3
under previously described conditions (Bibollet-Ruche et
al., 1998). The amplified env fragments were purified,
directly sequenced, and analyzed by phylogeny.
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To discriminate between HIV-1 groups O and M in the
pol gene, the following primers were used in a nested PCR.
A universal first round was done with 4235 (5-CCCTA-
CAATCCCCAAAGTCAAGG-3) and 4538 (5-TACTGC-
CCCTTCACCTTTCCA-3) primers and a second round
with either a group-M specific primer (4241M: 5-TA-
GAATCTATGAATAAAGAATTAAAGAA-3) and a uni-
versal primer (4481: 5-GCTGTCCCTGTAATAAAC-
CCG-3) or group O-specific primers (4241-O: 5-
TAGAAGCCATGAATAAGGAATTAAAATC-3; 4391-O:
5-TTTGTAATTCTGTTGTTTGTATTTGTGA-3) (Heyn-
drickx et al., 1998; Janssens et al., 1995).
Phylogenetic analysis
Nucleotide sequences were aligned using CLUSTAL W
with minor manual adjustments, bearing in mind the protein
sequences (Thompson et al., 1994). Regions that could not
be aligned unambigously, due to length or sequence vari-
ability, were omitted from the analysis. Phylogenetic trees
using the neighbor-joining method and reliability of the
branching orders using the bootstrap approach were imple-
mented with CLUSTAL W (Saitou and Nei, 1987). Genetic
distances were calculated with Kimura’s (1981) two-param-
eter method (ratio t/T  2.0). The newly determined HIV-1
env and gag sequences were aligned with known HIV-1
sequences representing the different genetic subtypes and
sub-subtypes and reference strains from the CRFs docu-
mented in West and West Central Africa (CRF01_AE,
CRF02_AG, CRF06_cpx, CRF11_cpx and CRF13_cpx)
(Peeters, 2000; Wilbe et al., 2002). To clearly identify
whether a sequence belonged to a subgroup corresponding
to a CRF within a certain subtype or not, phylogenetic
analysis was done for each sequence individually. Then,
different trees were constructed for each group of new
sequences that were thought to cluster together and, finally,
a general tree was obtained to visualize all the results. The
clustering of each new sequence was compared and should
be concordant between all trees. In the same way, for the
dual-reactive samples, phylogeny analyses were performed
on group M and O sequences against reference sequences in
the env gene and in the pol gene to confirm the amplification
with group-specific primers (phylogeny on a 220-bp frag-
ment is not significant but is informative in checking the
HIV-1 group). The reference strains used are indicated in
the legends of the phylogenetic trees.
Determination of syncytium-inducing capacity
PBMCs from the HIV-positive patients were co-culti-
vated with phytohemaglutinin (PHA)-stimulated lympho-
cytes from a HIV-negative human donor in RPMI-1640
medium (Biowhittaker, Verviers, Belgium) supplemented
with 15% heat-inactivated fetal calf serum (Gibco, Paisley,
Scotland), 0.03% L-glutamine (Gibco), 2 g of Polybrene
(Murex, Dartford, England) per milliliter, antibiotics, and
20 U of recombinant interleukin-2 (Boehringer, Mannheim,
Germany) per milliliter. The release of viral particles in the
culture supernatants was examined with a HIV p24 antigen-
capturing test (Innogenetics, Gent, Belgium).
Syncytium formation was determined with the MT-2
assay essentially as described by Koot et al. (1992). HIV-1
strains obtained from the initial culture were propagated by
short-term passage (7–10 days), and then 1 million infected
PBMCs were co-cultivated with 2 million MT-2 cells at a
concentration of 500,000 cells/ml. HIV-1 cultures were con-
sidered to exhibit syncytia if one multinucleated giant cell
per field of the light microscope was observed. We studied
the prediction of the phenotype based on the sequence of the
V3 loop, i.e., we examined whether basic or positively
charged amino acids (K, R, or H) at positions 11 and/or 25
in the V3 loop were present, and we calculated the global
charge of the V3 loop (De Jong et al., 1992; Fouchier et al.,
1992).
Statistics
Data were analyzed using Stata 7.0 software (Stata Cor-
poration, College Station, TX, USA). For prevalences of
HIV-1 group M, N, and O and HIV-2 infections, 95%
confidence intervals (CIS) were computed using the bino-
mial exact method. The trends over time were assessed by
use of the 2 test for trends. The global charge of the V3
loop in SI and NSI groups was described by the mean and
the standard deviation, after checking the distribution nor-
mality with the Shapiro–Francia W test. Comparisons be-
tween SI and NSI groups were then based on the two-
sample t test.
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